Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prevalence of Darunavir Resistance in the United States from 2010 to 2017.

AIDS research and human retroviruses - 1 Dec 2018

Brown Kimberley, Stewart Lisa, Whitcomb Jeannette M, Yang Dongmei, Nettles Richard E, Lathouwers Erkki

Abstract excerpt

The emergence and transmission of antiretroviral drug resistance have been and remain a concern among people living with human immunodeficiency virus (HIV)-1 infection. The protease inhibitor (PI) darunavir has been approved for use in the United States for more than 10 years and has demonstrated a high barrier to resistance. Previous analyses identified significant reductions in the prevalence of samples with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Darunavir
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to History, 21st Century

Share to HIV Protease Inhibitors

Share to Inhibitory Concentration 50

Share to Mutation

Share to United States

Source

Open in PubMed Open full text

Identifiers

PMID: 30148406
DOI: 10.1089/AID.2018.0100
PMCID: PMC6306664

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevalence of Darunavir Resistance in the United States from 2010 to 2017.PMID 30148406Read ↗

Trends in darunavir resistance-associated mutations and phenotypic resistance in commercially tested United States clinical samples between 2006 and 2012.Semantic proximity Read ↗

Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States.Semantic proximity Read ↗

Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society–USA PanelSemantic proximity Read ↗

HIV-1 drug resistance and resistance testing.Semantic proximity Read ↗

HIV-1 Drug Resistance Trends in the Era of Modern Antiretrovirals: 2018–2024Semantic proximity Read ↗

Clinical outcomes of once-daily darunavir in treatment-experienced patients with darunavir resistance-associated mutations through 48 weeks of treatment.Semantic proximity Read ↗

HIV-1 resistance rarely observed in patients using darunavir once-daily regimens across clinical studies.Semantic proximity Read ↗

Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted Human Immunodeficiency Virus Type 1 Drug Resistance in a Large US Clinic Population.Semantic proximity Read ↗

A detailed characterization of drug resistance during darunavir/ritonavir monotherapy highlights a high barrier to the emergence of resistance mutations in protease but identifies alternative pathways of resistance.Semantic proximity Read ↗

HIV-1 reverse transcriptase and protease mutations for drug-resistance detection among treatment-experienced and naïve HIV-infected individuals.Semantic proximity Read ↗

Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis.Semantic proximity Read ↗

Transmitted Drug Resistance Among Human Immunodeficiency Virus (HIV)-1 Diagnoses in the United States, 2014-2018.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.